Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
Launched by GE HEALTHCARE · Jun 30, 2006
Trial Information
Current as of May 27, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is ≥18 years old.
- • Subject must have been referred for an elective coronary angiography for one of several specified conditions.
- Exclusion Criteria:
- • The subject has impaired renal function with a serum creatinine level ≥1.7 mg/dL (150 μmol/L). If the institution's practising guideline(s) regarding the serum creatinine limits for receiving radiologic contrast medium are lower than 1.7 mg/dL (150 μmol/L), the investigator should follow the practising guideline(s) of their institution.
- • Subject has a known allergy to iodinated contrast agent
- • Subject has atrial fibrillation/flutter or any irregular heart rhythm considered to interfere with temporal acquisition of cardiac CT images.
- • The subject's resting heart rate is 66-100 bpm and β-blocker therapy is contraindicated.
- • Use of nitroglycerin is contraindicated.
- • Subject has had a prior CABG procedure.
- • Subject has a metal cardiac stent in place or artificial heart valve(s).
- • Subject has had a prior pacemaker or internal defibrillator lead implantation. Subject must agree to discontinue metformin day of and for 48 hours after the CTA procedure.
About Ge Healthcare
GE Healthcare is a leading global medical technology and digital solutions innovator, dedicated to improving patient outcomes through advanced imaging, monitoring, and diagnostics. With a commitment to enhancing healthcare delivery, GE Healthcare develops cutting-edge technologies and clinical applications that empower healthcare professionals to make informed decisions. By leveraging extensive research and development capabilities, the organization actively sponsors clinical trials aimed at validating new therapies and medical devices, ensuring that they meet the highest standards of safety and efficacy. Through collaboration with healthcare providers and institutions, GE Healthcare strives to drive innovation and improve the efficiency of healthcare systems worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Princeton, New Jersey, United States
Patients applied
Trial Officials
Veronica Reichl
Study Director
GE Healthcare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials